Iridian Asset Management LLC Cel Sci Corp Call Options Transaction History

Iridian Asset Management LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 10, 2022	SELL	$7.1 - $12.82 $106,500 - $192,300	-15,000 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$7.64 - $12.49 $114,600 - $187,350	-15,000 Reduced 50.0%	15,000 $165,000
Q2 2021 Aug 11, 2021	BUY	$8.68 - $27.49 $23,080 - $73,095	2,659 Added 9.73%	30,000 $260,000
Q1 2021 May 11, 2021	BUY	$12.0 - $27.64 $172,092 - $396,385	14,341 Added 110.32%	27,341 $416,000
Q4 2020 Feb 08, 2021	SELL	$11.05 - $16.62 $108,290 - $162,876	-9,800 Reduced 42.98%	13,000 $152,000
Q3 2020 Nov 02, 2020	BUY	$11.69 - $14.54 $266,532 - $331,512	22,800 New	22,800 $291,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Iridian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Iridian Asset Management LLC with notifications on news.